STAT Plus: Did Kennedy just stack the deck on FDA oversight of peptides?
Lab Dish
Paul Knoepfler writes STAT’s Lab Dish column, which covers regenerative medicine. He leads the University of California-Davis’ Knoepfler Lab. Lab Dish examines cell therapies, gene editing, regulation, CRISPR, and more.
Latest
STAT Plus: Landmines await Vinay Prasad’s successor at the FDA
STAT Plus: 6 key dilemmas as human embryo models get ever closer to the real thing
STAT Plus: Excitement and wariness as FDA shifts to much more flexible cell and gene therapy oversight
STAT Plus: FDA drug center’s new acting director fits a pattern of risky, internal contradictions among agency leadership
What will be born of the marriage of de-extinction firm Colossal and animal cloning biotech Viagen?
STAT Plus: Despite the drama and hype from influencers, longevity science is making real progress
STAT Plus: Japan’s green light for making human embryos from stem cells takes us into uncharted territory
All Coverage
